Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 -0.57%89 Net Debt Paydown Yield % is 0.01% as of Aug. 20, 2026, which is 89% below its 10-year median of 0.09. GuruFocus rates BOM:543960 with a GF Score™ of 89/100 and a GF Value™ of ₹1,676.13 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,154 Biotechnology companies, Concord Biotech ranks worse than 51.91% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Concord Biotech's Net Debt Paydown Yield % was 0.01%.
Concord Biotech (BOM:543960) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Concord Biotech Net Debt Paydown Yield % Related Terms
Concord Biotech Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Concord Biotech's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.01% mean?
Concord Biotech (BOM:543960) has a Net Debt Paydown Yield % of 0.01% as of Aug. 20, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Concord Biotech and its competitors. This is 89% below median its historical median of 0.09. Over the past decade, Concord Biotech's Net Debt Paydown Yield % has ranged from 0.01 to 0.31. According to the industry distribution chart, Concord Biotech ranks #599 out of 1154 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Concord Biotech's Net Debt Paydown Yield % too high?
Concord Biotech's current Net Debt Paydown Yield % of 0.01% is 89% below median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.31. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Concord Biotech's value of 0.01% is 66.7% below this industry median. Based on the distribution chart, Concord Biotech ranks #599 out of 1154 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #599 out of 1154 companies for Net Debt Paydown Yield %. This places Concord Biotech in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. Concord Biotech's value of 0.01% is 66.7% below this benchmark. Historically, Concord Biotech's own Net Debt Paydown Yield % has ranged from 0.01 to 0.31 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.03, Concord Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,154 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Net Debt Paydown Yield % of 0.01% is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Net Debt Paydown Yield % is 0.01%, which is 89% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,676.13, compared to a current price of ₹1,576.00 — trading 6% below its estimated fair value. The current Net Debt Paydown Yield % is 0.01%, which is 89% below median its 10-year median of 0.09 and 66.7% below the Biotechnology industry median of 0.03. Concord Biotech's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Net Debt Paydown Yield % is 0.01% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,576.00 is trading 6% below its estimated GF Value™ of ₹1,676.13.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for BOM:543960:
Net Debt Paydown Yield %: 0.01% (89% below median its 10-year median of 0.09)
GF Value™: ₹1,676.13 vs. price of ₹1,576.00 (6% below fair value)
Industry Position: 66.7% below the Biotechnology median (#599 of 1154)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for BOM:543960
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
